$3.70
2.12% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US5171251003
Symbol
LRMR

Larimar Therapeutics Inc Stock price

$3.70
+0.25 7.25% 1M
+0.47 14.55% 6M
-0.17 4.39% YTD
-3.92 51.44% 1Y
+1.58 74.53% 3Y
-7.50 66.96% 5Y
-439.94 99.17% 10Y
-233.30 98.44% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
-0.08 2.12%
ISIN
US5171251003
Symbol
LRMR
Industry

Key metrics

Basic
Market capitalization
$312.9m
Enterprise Value
$155.4m
Net debt
positive
Cash
$157.5m
Shares outstanding
64.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
2.2
Financial Health
Equity Ratio
85.8%
Return on Equity
-46.9%
ROCE
-71.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-105.0m | $-132.1m
EBIT
$-105.3m | $-137.4m
Net Income
$-95.2m | $-125.4m
Free Cash Flow
$-87.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-107.8% | -45.9%
EBIT
-107.1% | -51.2%
Net Income
-111.2% | -55.6%
Free Cash Flow
-140.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.5
FCF per Share
$-1.4
Short interest
17.4%
Employees
65
Rev per Employee
$0.0
Show more

Is Larimar Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Larimar Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Larimar Therapeutics Inc forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Larimar Therapeutics Inc forecast:

Buy
94%
Hold
6%

Financial data from Larimar Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
25% 25%
-
- Research and Development Expense 87 87
141% 141%
-
-105 -105
108% 108%
-
- Depreciation and Amortization 0.33 0.33
6% 6%
-
EBIT (Operating Income) EBIT -105 -105
107% 107%
-
Net Profit -95 -95
111% 111%
-

In millions USD.

Don't miss a Thing! We will send you all news about Larimar Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Larimar Therapeutics Inc Stock News

Neutral
GlobeNewsWire
12 days ago
BALA CYNWYD, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten public offering of 21,562,500 shares of its common stock, which includes the exercise in full of the underwriters' option ...
Neutral
GlobeNewsWire
14 days ago
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its previously announced underwritten public offering of 18,750,000 shares of its common stock at a price to the public of $3.20 per share. The aggregate gross ...
Neutral
GlobeNewsWire
14 days ago
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to pu...
More Larimar Therapeutics Inc News

Company Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. It also focuses on using its intracellular platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is headquartered in Bala Cynwyd, Pennsylvania.

Head office United States
CEO Carole Ben-Maimon
Employees 65
Founded 2005
Website larimartx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today